Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide for Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
NCT00362570Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- May 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in anaplastic oligodendroglioma (AO) and oligoastrocytoma (OA), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Progression-Free Survival and Response Rate. Started May 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
anaplastic oligodendroglioma (AO)oligoastrocytoma (OA)
Beyond the preview
Go deeper on NCT00362570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362570.